Please ensure Javascript is enabled for purposes of website accessibility

Why Heartware International's Shares Are Sinking 12% Today

By Todd Campbell - May 4, 2016 at 12:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Disappointing first-quarter financials sent shares reeling.

SOURCE: HEARTWARE INTERNATIONAL, INC.

What: After reporting first-quarter financial results that fell shy of industry watchers' forecasts, shares of Heartware International (NASDAQ: HTWR) were tumbling by 12.4% at 11:30 a.m. EST.

So what: The maker of implantable pumps, which can assist heart function, reported sales and losses of $55.07 milion and $0.95 per share, respectively, in the first quarter. Those results were short of analysts' projections for sales of $59.9 million and a loss of $0.79 per share.

Revenue was down from $70 million in the first quarter of 2015, and it marks yet another in a string of sequential quarterly sales declines for the company. 

HTWR Revenue (TTM) Chart

HTWR Revenue (TTM) data by YCharts.

In the company's earnings release, management reported greater than 20% declines overseas and in the United States. U.S. sales dropped because the company's implants are only approved as a bridge to transplant, rather than a destination therapy. Because reimbursement is easier for destination therapy, more patients are being treated that way.

Overall, 578 HVAD Systems were sold globally last quarter, a 19% decrease from the first quarter of 2015.  

Now what: It's been a struggle for Heartware investors. The company's efforts to develop a smaller version of its pumps have been delayed because of adverse events. Research is ongoing into the cause of those events, but no timeline has been given yet on when trials may resume, or if the device needs to be scrapped and reengineered. Additionally, while the company is working on gaining approval as a destination therapy, the current trends away from bridge-to-transplant treatment are creating major headwinds.

Last quarter, the company's operating expenses totaled $47 million, and the company has $189 million in cash and cash-like investments on its books, down from $244 million at the end of 2015, so the company could need to raise some additional funding at some point. Overall, until Heartware can win approval for its devices as a destination therapy, reverse the slide in unit volume, or right-size expenses so that it can become profitable, there are probably better investments to consider than this company's stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.